vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and MGIC INVESTMENT CORP (MTG). Click either name above to swap in a different company.
MGIC INVESTMENT CORP is the larger business by last-quarter revenue ($298.7M vs $183.1M, roughly 1.6× Amphastar Pharmaceuticals, Inc.). MGIC INVESTMENT CORP runs the higher net margin — 56.7% vs 13.3%, a 43.3% gap on every dollar of revenue. On growth, MGIC INVESTMENT CORP posted the faster year-over-year revenue change (-0.9% vs -1.8%). MGIC INVESTMENT CORP produced more free cash flow last quarter ($230.2M vs $24.6M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs 0.7%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
MGIC Investment Corporation NYSE: MTG ("MGIC") is a provider of private mortgage insurance in the United States. The company is headquartered in Milwaukee, Wisconsin.
AMPH vs MTG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $298.7M |
| Net Profit | $24.4M | $169.3M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 71.2% |
| Net Margin | 13.3% | 56.7% |
| Revenue YoY | -1.8% | -0.9% |
| Net Profit YoY | -35.7% | -8.3% |
| EPS (diluted) | $0.51 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $298.7M | ||
| Q3 25 | $191.8M | $304.5M | ||
| Q2 25 | $174.4M | $304.2M | ||
| Q1 25 | $170.5M | $306.2M | ||
| Q4 24 | $186.5M | $301.4M | ||
| Q3 24 | $191.2M | $306.6M | ||
| Q2 24 | $182.4M | $305.3M | ||
| Q1 24 | $171.8M | $294.4M |
| Q4 25 | $24.4M | $169.3M | ||
| Q3 25 | $17.4M | $191.1M | ||
| Q2 25 | $31.0M | $192.5M | ||
| Q1 25 | $25.3M | $185.5M | ||
| Q4 24 | $38.0M | $184.7M | ||
| Q3 24 | $40.4M | $200.0M | ||
| Q2 24 | $37.9M | $204.2M | ||
| Q1 24 | $43.2M | $174.1M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 71.2% | ||
| Q3 25 | 13.2% | 77.2% | ||
| Q2 25 | 24.2% | 80.9% | ||
| Q1 25 | 21.9% | 76.6% | ||
| Q4 24 | 24.2% | 77.9% | ||
| Q3 24 | 29.8% | 82.9% | ||
| Q2 24 | 30.3% | 85.1% | ||
| Q1 24 | 27.9% | 74.7% |
| Q4 25 | 13.3% | 56.7% | ||
| Q3 25 | 9.0% | 62.8% | ||
| Q2 25 | 17.8% | 63.3% | ||
| Q1 25 | 14.8% | 60.6% | ||
| Q4 24 | 20.4% | 61.3% | ||
| Q3 24 | 21.1% | 65.2% | ||
| Q2 24 | 20.8% | 66.9% | ||
| Q1 24 | 25.1% | 59.1% |
| Q4 25 | $0.51 | $0.75 | ||
| Q3 25 | $0.37 | $0.83 | ||
| Q2 25 | $0.64 | $0.81 | ||
| Q1 25 | $0.51 | $0.75 | ||
| Q4 24 | $0.74 | $0.71 | ||
| Q3 24 | $0.78 | $0.77 | ||
| Q2 24 | $0.73 | $0.77 | ||
| Q1 24 | $0.81 | $0.64 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $369.0M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $5.1B |
| Total Assets | $1.6B | $6.6B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $369.0M | ||
| Q3 25 | $276.2M | $266.9M | ||
| Q2 25 | $231.8M | $294.9M | ||
| Q1 25 | $236.9M | $207.0M | ||
| Q4 24 | $221.6M | $229.5M | ||
| Q3 24 | $250.5M | $288.6M | ||
| Q2 24 | $217.8M | $281.8M | ||
| Q1 24 | $289.6M | $431.3M |
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $5.1B | ||
| Q3 25 | $776.7M | $5.2B | ||
| Q2 25 | $757.5M | $5.2B | ||
| Q1 25 | $751.3M | $5.1B | ||
| Q4 24 | $732.3M | $5.2B | ||
| Q3 24 | $727.7M | $5.3B | ||
| Q2 24 | $713.3M | $5.1B | ||
| Q1 24 | $672.4M | $5.1B |
| Q4 25 | $1.6B | $6.6B | ||
| Q3 25 | $1.7B | $6.6B | ||
| Q2 25 | $1.6B | $6.5B | ||
| Q1 25 | $1.6B | $6.5B | ||
| Q4 24 | $1.6B | $6.5B | ||
| Q3 24 | $1.5B | $6.7B | ||
| Q2 24 | $1.5B | $6.5B | ||
| Q1 24 | $1.6B | $6.5B |
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $230.8M |
| Free Cash FlowOCF − Capex | $24.6M | $230.2M |
| FCF MarginFCF / Revenue | 13.4% | 77.1% |
| Capex IntensityCapex / Revenue | 4.5% | 0.2% |
| Cash ConversionOCF / Net Profit | 1.35× | 1.36× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $851.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $230.8M | ||
| Q3 25 | $52.6M | $215.4M | ||
| Q2 25 | $35.6M | $183.0M | ||
| Q1 25 | $35.1M | $223.7M | ||
| Q4 24 | $29.0M | $182.4M | ||
| Q3 24 | $60.0M | $182.9M | ||
| Q2 24 | $69.1M | $169.2M | ||
| Q1 24 | $55.3M | $190.5M |
| Q4 25 | $24.6M | $230.2M | ||
| Q3 25 | $47.2M | $215.1M | ||
| Q2 25 | $25.0M | $183.0M | ||
| Q1 25 | $24.4M | $223.5M | ||
| Q4 24 | $16.6M | $181.9M | ||
| Q3 24 | $46.2M | $182.5M | ||
| Q2 24 | $63.1M | $169.0M | ||
| Q1 24 | $46.5M | — |
| Q4 25 | 13.4% | 77.1% | ||
| Q3 25 | 24.6% | 70.6% | ||
| Q2 25 | 14.3% | 60.1% | ||
| Q1 25 | 14.3% | 73.0% | ||
| Q4 24 | 8.9% | 60.3% | ||
| Q3 24 | 24.1% | 59.5% | ||
| Q2 24 | 34.6% | 55.3% | ||
| Q1 24 | 27.1% | — |
| Q4 25 | 4.5% | 0.2% | ||
| Q3 25 | 2.8% | 0.1% | ||
| Q2 25 | 6.1% | 0.0% | ||
| Q1 25 | 6.3% | 0.0% | ||
| Q4 24 | 6.7% | 0.2% | ||
| Q3 24 | 7.2% | 0.1% | ||
| Q2 24 | 3.3% | 0.1% | ||
| Q1 24 | 5.1% | 0.0% |
| Q4 25 | 1.35× | 1.36× | ||
| Q3 25 | 3.03× | 1.13× | ||
| Q2 25 | 1.15× | 0.95× | ||
| Q1 25 | 1.39× | 1.21× | ||
| Q4 24 | 0.76× | 0.99× | ||
| Q3 24 | 1.48× | 0.91× | ||
| Q2 24 | 1.82× | 0.83× | ||
| Q1 24 | 1.28× | 1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
MTG
Segment breakdown not available.
